Serum gastrin and pepsinogens do not correlate with the different grades of severity of gastro-oesophageal reflux disease: A matched case-control study

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 4, 2008, Pages 491-496

  Monkemuller, K ^b   Neumann, H ^b   Nocon, M ^c   Vieth, M ^d   Labenz, J ^e   Willich, S N ^c   Stolte, M ^d   Hocker, M ^f   Jaspersen, D ^g   Lind, T ^h   Malfertheiner, P ^a,b  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d INSTITUTE OF PATHOLOGY   (Germany)

^e Ev Jung Stilling Krankenhaus   (Germany)

^f ASTRAZENECA   (United Kingdom)

^g KLINIKUM FULDA   (Germany)

^h ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; PEPSINOGEN; PEPSINOGEN I; PEPSINOGEN II;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; ESOPHAGITIS; ESOPHAGUS MUCOSA; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRIC ACID; GASTRIC MUCOSA; GASTRINS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPSINOGENS; PROSPECTIVE STUDIES;

EID: 47749087060     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03769.x     Document Type: Article

References (34)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006 101 : 1900 20.
2. Kahrilas PJ, Shi G, Manka M, Joehl RJ. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000 118 : 688 95.
3. Lin S, Ke M, Xu J, Kahrilas PJ. Impaired esophageal emptying in reflux disease. Am J Gastroenterol 1994 89 : 1003 6.
4. Collen MJ, Johnson DA. Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagus. Dig Dis Sci 1992 37 : 570 6.
5. Mulholland MW, Reid BJ, Levine DS, Rubin CE. Elevated gastric acid secretion in patients with Barrett's metaplastic epithelium. Dig Dis Sci 1989 34 : 1329 34.
6. Naito Y, Ito M, Watanabe T, et al. Biomarkers in patients with gastric inflammation: a systematic review. Digestion 2005 72 : 164 80.
7. Hirschowitz BI, Tim LO, Helman CA, Molina E. Bombesin and G-17 dose responses in duodenal ulcer and controls. Dig Dis Sci 1985 30 : 1092 103.
8. Sipponen P, Ranta P, Helske T, et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol 2002 37 : 785 91.
9. Germana B, Di Mario F, Cavallaro LG, et al. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care. Dig Liver Dis 2005 37 : 501 8.
10. Väänanen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003 15 : 885 91.
11. Webb PM, Hengels KJ, Møller H, et al. The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. EUROGAST Study Group. Gastroenterology 1994 107 : 1335 44.
12. Kulig M, Nocon M, Vieth M, et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004 57 : 580 9.
13. Jaspersen D, Kulig M, Labenz J, et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther 2003 17 : 1515 20.
14. Vieth M, Kulig M, Leodolter A, et al. Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus. Aliment Pharmacol Ther 2006 23 : 313 9.
15. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003 18 : 767 76.
16. Nocon M, Labenz J, Jaspersen D, et al. Nighttime heartburn in patients with gastroesophageal reflux disease under routine care. Digestion 2008 77 : 69 72.
17. Nocon M, Labenz J, Jaspersen D, et al. Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study. J Gastroenterol Hepatol 2007 22 : 1728 31.
18. Nocon M, Labenz J, Jaspersen D, et al. Long-term treatment of patients with gastro-oesophageal reflux disease in routine care - results from the ProGERD study. Aliment Pharmacol Ther 2007 25 : 715 22.
19. Labenz J, Nocon M, Lind T, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 2006 101 : 2457 62.
20. Leodolter A, Nocon M, Kulig M, Willich SN, Malfertheiner P, Labenz J. Gastro esophageal reflux disease is associated with absence from work: results from a prospective cohort study. World J Gastroenterol 2005 11 : 7148 51.
21. Jaspersen D, Labenz J, Willich SN, et al. Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD study. Dig Liver Dis 2006 38 : 233 8.
22. Vieth M, Peitz U, Labenz J, et al. What parameters are relevant for the histological diagnosis of gastroesophageal reflux disease without Barrett's mucosa? Dig Dis 2004 22 : 196 201.
23. Labenz J, Jaspersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004 99 : 1652 6.
24. Malfertheiner P, Lind T, Willich S, et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005 54 : 746 51.
25. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999 45 : 172 80.
26. Sydney Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 1996 20 : 1161 81.
27. Dvorak K, Fass R, Dekel R, et al. Esophageal acid exposure at pH < or = 2 is more common in Barrett's esophagus patients and is associated with oxidative stress. Dis. Esophagus 2006 19 : 366 72.
28. Nardone G, Rocco A, Staibano S, et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment Pharmacol Ther 2005 22 : 1139 46.
29. Mossi S, Meyer-Wyss B, Renner EL, et al. Influence of Helicobacter pylori, sex, and age on serum gastrin and pepsinogen concentrations in subjects without symptoms and patients with duodenal ulcers. Gut 1993 34 : 752 6.
30. Gisbert JP, Boixeda D, Al-Mostafa A, et al. Basal and stimulated gastrin and pepsinogen levels after eradication of Helicobacter pylori: a 1-year follow-up study. Eur J Gastroenterol Hepatol 1999 11 : 189 200.
31. Ito M, Haruma K, Kaya S, et al. Serological comparison of serum pepsinogen and anti-parietal cell antibody levels between Japanese and German patients. Eur J Gastroenterol Hepatol 2002 14 : 123 7.
32. Fujiwara Y, Higuchi K, Shiba M, et al. Differences in clinical characteristics between patients with endoscopy-negative reflux disease and erosive esophagitis in Japan. Am J Gastroenterol 2005 100 : 754 8.
33. Sipponen P, Vauhkonen M, Helske T, et al. Low circulating levels of gastrin-17 in patients with Barrett's esophagus. World J Gastroenterol 2005 11 : 5988 92.
34. Yoshikawa I, Murata I, Kume K, et al. Serum pepsinogen can predict response to H2-receptor antagonist in patients with functional dyspepsia. Aliment Pharmacol Ther 2002 16 : 1805 9.